2256 (2256) Fair Value & Analysis

Healthcare · Market cap HK$8.0B

2 2256 2256 · HK

PriceHK$11.23

Fair ValueHK$1.47

Upside-86.9%

Quality61/100

Watch 2256 for free — get notified when fair value or trend changes. Watch for free

Evidence: High Range HK$1.40 – HK$1.84

Fair value as of: Jul 2, 2026

From 24 valuation models · updated today

Share price +18.0% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$8.70 – HK$19.62 · fair‑value band HK$1.40 – HK$1.84 · the HK$11.23 price screens above the HK$1.47 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

2256 (2256) currently trades at HK$11.23, while our model-based Fair Value estimate is HK$1.47 — implying the stock looks roughly 86.9% overvalued today. We read business quality at 61/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

Over the trailing twelve months, 2256 generated revenue of HK$612M at a net margin of 9.0%. It earns a return on equity of 2.9%. The balance sheet holds a net cash position of HK$446M. The stock trades on a trailing P/E of 112.3. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$612M

Revenue growth (YoY) -100%

Net margin 9.0%

Return on equity 2.9%

Free cash flow HK$73.8M FY2025

P/E ratio 112.3

More key figures

Operating margin 4.6%

EPS (TTM) HK$0.5100

EPS growth (YoY) +59.4%

Net cash HK$446M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

2256 reported revenue of HK$596M in FY2025 versus HK$22.7M in FY2021, a compound +126.4%/yr. Reported net income was HK$53.8M in FY2025.

Revenue +126.4%/yr

FY21 HK$22.7M

FY22 HK$0

FY23 HK$19.1M

FY24 HK$504M

FY25 HK$596M

Net income

FY21 −HK$1.8B

FY22 −HK$498M

FY23 −HK$432M

FY24 HK$28.3M

FY25 HK$53.8M

Is 2256 fairly valued? → Check now

Similar stocks

6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX	7,746 MXN	5,617 MXN	-27%
Regeneron Pharmaceuticals, Inc REGN	$635.45	$547.01	-14%
UCB SA UCB	€247.60	€180.06	-27%
argenx SE ARGNF	$900.00	$390.80	-57%
Alnylam Pharmaceuticals, Inc ALNY	$286.41	$106.81	-63%
Samsung Biologics Co 207940	1,000,000 KRW	1,091,384 KRW	+9%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 2256 (2256) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$1.47 versus a price of HK$11.23 — about −87% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 2256?

Our model-based fair value for 2256 is HK$1.47 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$11.23.

What is the quality score of 2256?

2256 has a Quality Score of 61/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 2256 (2256)?

2256 reported trailing-twelve-month revenue of about HK$612M (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 2256?

The net profit margin of 2256 is about 9.0%, meaning it keeps roughly 9.0% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.